用Pembrolizumab治疗的囊细胞肉瘤:一个病例报告和文献综述
Daniel Huff1, Shannon Fortin Ensign2, Margaret S Ryan3
1Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.
Journal of immunotherapy and precision oncology
|December 25, 2023
概括
囊性肉瘤 (HS) 是一种罕见的癌症. 一名患有晚期HS和高PD-L1表达的患者接受了化疗,pembrolizumab和干细胞移植,存活了26个月.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 囊性肉瘤 (HS) 是一种罕见的血液性恶性瘤.
- 传统治疗的平均存活时间仅为6个月.
更多相关视频
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
444
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
